A Combination Vaccine against Encephalomyocarditis Virus and Porcine Circovirus Type 2 Induces Protective Immune Response in Pigs — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
A Combination Vaccine against Encephalomyocarditis Virus and Porcine Circovirus Type 2 Induces Protective Immune Response in Pigs
College of Life Science, Henan Agricultural University, Zhengzhou, China
,
College of Life Science, Henan Agricultural University, Zhengzhou, China
,
College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
,
College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
,
College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
,
College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
1 College of Life Science, Henan Agricultural University, Zhengzhou, China
2 College of Life Science, Henan Agricultural University, Zhengzhou, China
3 College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
4 College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
5 College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
6 College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
Encephalomyocarditis virus (EMCV) and porcine circovirus type 2 (PCV2) are common causative agents with high infection rate in pig farms, thus a combined vaccine against both EMCV and PCV2 is highly desirable. In the present study, we developed an oil-adjuvant combination vaccine candidate comprising of inactivated EMCV and PCV2, and evaluated the safety and immunogenicity in mice and swine. The combination vaccine was found to elicit serum antibodies and had strong neutralization activity, more importantly, passive immunization with the combined vaccine protected swine against either EMCV or PCV2 lethal infections, whereas the monovalent vaccine only prevent the one of two virus challenge. Our results demonstrated the combined vaccine was safe and induced protective immune response in mice and swine as evident from sero-conservation as well as challenge studies in swine, indicating that component vaccines did not interfere with the immunogenicity of each other.
Gelmetti, D., Meroni, A., Brocchi, E., et al. (2006) Pathogenesis of Encephalomyocarditis Experimental Infection in Young Piglets: A Potential Animal Model to Study Viral Myocarditis. Veterinary Research, 37, 15-23. https://doi.org/10.1051/vetres:2005041
Juncker-Voss, M., Prosl, H., Lussy, H., et al. (2003) Screening for Antibodies against Zoonotic Agents among Employees of the Zoological Garden of Vienna, Schonbrunn, Austria. Berliner und Munchener Tierarztliche Wochenschrift, 117, 404-409.
LaRue, R., Myers, S., Brewer, L., et al. (2003) A Wild-Type Porcine Encephalomyocarditis Virus Containing a Short Poly (C) Tract Is Pathogenic to Mice, Pigs, and Cynomolgus Macaques. Journal of Virology, 77, 9136-9146. https://doi.org/10.1128/JVI.77.17.9136-9146.2003
Billinis, C., Paschaleri-Papadopoulou, E., Psychas, V., et al. (1999) Persistence of Encephalomyocarditis Virus (EMCV) Infection in Piglets. Veterinary Microbiology, 70, 171-177. https://doi.org/10.1016/S0378-1135(99)00137-6
Ge, X., Wang, F., Guo, X., et al. (2012) Porcine Circovirus Type 2 and Its Associated Diseases in China. Virus Research, 164, 100-106. https://doi.org/10.1016/j.virusres.2011.10.005
Park, C., Jeong, J., Choi, K., et al. (2016) Efficacy of a New Bivalent Vaccine of Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae (Fostera TM PCV MH) under Experimental Conditions. Vaccine, 34, 270-275. https://doi.org/10.1016/j.vaccine.2015.11.034
Jeoung, H.Y., Shin, B.H., Jeong, W.S., et al. (2012) A Novel Vaccine Combined with an Alum Adjuvant for Porcine Encephalomyocarditis Virus (EMCV)-Induced Reproductive Failure in Pregnant Sows. Research in Veterinary Science, 93, 1508-1511. https://doi.org/10.1016/j.rvsc.2012.02.012
Pogranichniy, R.M., Yoon, K.J., Yaeger, M., et al. (2004) Efficacy of Experimental Inactivated PCV2 Vaccines for Preventing PMWS in CDCD Pigs. Proc Annu Meet Am Assoc Swine Vet, Lowa, 35, 443-444.
Fraile, L., Grau-Roma, L., Sarasola, P., et al. (2012) Inactivated PCV2 One Shot Vaccine Applied in 3-Week-Old Piglets: Improvement of Production Parameters and Interaction with Maternally Derived Immunity. Vaccine, 30, 1986-1992. https://doi.org/10.1016/j.vaccine.2012.01.008
Reed, L.J. and Muench, H. (1938) A Simple Method of Estimating Fifty Per Cent Endpoints. American Journal of Epidemiology, 27, 493-497. https://doi.org/10.1093/oxfordjournals.aje.a118408
Chang, H.T., Liu, H.M., Li, Y.T., et al. (2016) Analysis of Pathogenicity in Piglets Concurrent Infection with Encephalomyocarditis Virus under Immunosuppression Caused by Porcine Circovirus Type 2. Acta veterinaria et zootechnica Sinica, 47, 1435-1442.
Hunter, P., Swanepoel, S.P., Esterhuysen, J.J., et al. (1998) The Efficacy of an Experimental Oil-Adjuvanted Encephalomyocarditis Vaccine in Elephants, Mice and Pigs. Vaccine, 16, 55-61. https://doi.org/10.1016/S0264-410X(97)00158-8
McLelland, D.J., Kirkland, P.D., Rose, K.A., Dixon, R.J. and Smith, N. (2005) Serologic Responses of Barbary Sheep (Ammotragus lervia), Indian Antelope (Antilope cervicapra), Wallaroos (Macropus robustus), and Chimpanzees (Pan troglodytes) to an Inactivated Encephalomyocarditis Virus Vaccine. Journal of Zoo and Wildlife Medicine, 36, 69-73. https://doi.org/10.1638/03-054
Chae, C. (2012) Commercial Porcine Circovirus Type 2 Vaccines: Efficacy and Clinical Application. The Veterinary Journal, 194, 151-157. https://doi.org/10.1016/j.tvjl.2012.06.031
Seo, H.W., Han, K., Kim, D., et al. (2011) Effects of an Inactivated Porcine Circovirus Type 2 (PCV2) Vaccine on PCV2 Virus Shedding in Semen from Experimentally Infected Boars. Clinical and Vaccine Immunology, 18, 1091-1096. https://doi.org/10.1128/CVI.05027-11
Yang, K., Li, W., Niu, H., et al. (2012) Efficacy of Single Dose of an Inactivated Porcine Circovirus Type 2 (PCV2) Whole-Virus Vaccine with Oil Adjuvant in Piglets. Acta Veterinaria Scandinavica, 54, 67. https://doi.org/10.1186/1751-0147-54-67
Patriarca, P.A., Wright, P.F. and John, T.J. (1991) Factors Affecting the Immunogenicity of Oral Poliovirus Vaccine in Developing Countries: Review. Reviews of Infectious Diseases, 13, 926-939. https://doi.org/10.1093/clinids/13.5.926
Guy, B., Barban, V., Mantel, N., Aguirre, M., Gulia, S., Pontvianne, J., et al. (2009) Evaluation of Interferences between Dengue Vaccine Serotypes in a Monkey Model. The American Journal of Tropical Medicine and Hygiene, 80, 302-311.
Anderson, K.B., Gibbons, R.V., Edelman, R., Eckels, K.H., Putnak, R.J., Innis, B.L., et al. (2011) Interference and Facilitation between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate. The Journal of Infectious Diseases, 204, 442-450. https://doi.org/10.1093/infdis/jir279
Sabchareon, A., Lang, J., Chanthavanich, P., Yoksan, S., Forrat, R., Attanath, P., et al. (2002) Safety and Immunogenicity of Tetravalent Live-Attenuated Dengue Vaccines in Thai Adult Volunteers: Role of Serotype Concentration, Ratio, and Multiple Doses. The American Journal of Tropical Medicine and Hygiene, 66, 264-272. https://doi.org/10.4269/ajtmh.2002.66.264
Sun, W., Edelman, R., Kanesa-Thasan, N., Eckels, K.H., Putnak, J.R., King, A.D., et al. (2003) Vaccination of Human Volunteers with Monovalent and Tetravalent Live Attenuated Dengue Vaccine Candidates. The American Journal of Tropical Medicine and Hygiene, 69, 24-31. https://doi.org/10.4269/ajtmh.2003.69.6_suppl.0690024
Kitchener, S., Nissen, M., Nasveld, P., Forrat, R., Yoksan, S., Lang, J., et al. (2006) Immunogenicity and Safety of Two Live-Attenuated Tetravalent Dengue Vaccine Formulations in Healthy Australian Adults. Vaccine, 24, 1238-1241. https://doi.org/10.1016/j.vaccine.2005.09.029